Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734393 | 0.87 | LMNA (0.68) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL22735643 | 0.87 | ALDH1A1 (0.64) | LMNAALDH1A1SMN1; SMN2TSHRGAA | |
| SCHEMBL22735789 | 0.84 | THRB (0.62) | LMNAMAPTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL22735650 | 0.79 | LMNA (0.75) | LMNAMAPTPOLBALDH1A1GAA | |
| SCHEMBL22735638 | 0.79 | ALDH1A1 (0.67) | LMNAALDH1A1SMN1; SMN2TSHRGAA | |
| SCHEMBL22735814 | 0.78 | TP53 (0.56) | LMNAMAPTTP53 | |
| SCHEMBL22734475 | 0.76 | THRB (0.68) | LMNAMAPTALDH1A1GAATP53 | |
| SCHEMBL22734758 | 0.76 | LMNA (0.52) | LMNAMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL22735666 | 0.72 | LMNA (0.59) | LMNAMAPTPOLBTP53 | |
| SCHEMBL24247543 | 0.70 | TP53 (0.39) | LMNAALDH1A1SMN1; SMN2TSHRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | BET1, BRD4, BRD3 | LMNA 2598/4885MAPT 1856/4885POLB 569/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | LMNA 2781/4885MAPT 1820/4885POLB 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.